Browse by Audience
Skip to content
Papers of the Week
Response to erenumab assessed by HIT-6 is modulated by genetic factors and arterial hypertension – an explorative cohort study.
Abstract
Response predictors to erenumab (ERE) in migraine patients would benefit their clinical management. We investigate associations between patients' clinic characteristics and polymorphisms at CALCRL and RAMP1 genes and response to ERE treatment measured as clinically meaningful improvement of the headache impact test 6 (HIT-6) score.